Kala Pharmaceuticals price target lowered to $18 from $21 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Kala Pharmaceuticals to $18 from $21 and keeps a Buy rating on the shares following the Q1 report. The firm says positive data from the CHASE trial may allow the company to advance KPI-012 into a second pivotal trial to support a biologics license application submission.